NEW DELHI (Friday, March 27, 2026) — A collaborative global analysis has found that stopping “preventive” medications in frail, older adults does not increase the risk of death, hospitalization, or major cardiovascular events. The findings, published in the journal BMC Geriatrics, challenge the long-held medical practice of maintaining lifelong preventive drug regimens for patients with limited life expectancy or high frailty.
The Study: Re-evaluating Polypharmacy
The research was conducted by an international team, including experts from the ICMR-National Institute for Research in Bacterial Infections (Kolkata) and Sweden’s Karolinska Institutet. They analyzed multiple studies to determine if “de-prescribing”—the planned process of reducing or stopping medications—led to adverse health outcomes.
- Target Group: Older adults (typically 65+) classified as “frail” or having multiple chronic conditions.
- Medications Studied: Primary preventive drugs such as statins (for cholesterol), antihypertensives (for blood pressure), and bisphosphonates (for bone density).
- Key Findings: * No significant increase in mortality or hospitalization rates.
- No rise in Major Adverse Cardiovascular Events (MACE).
- No increased risk of falls or fractures, which are leading causes of disability in seniors.
- No recorded reduction in the quality of life.
[Image: Infographic showing the “De-prescribing Process”: Review > Identify > Prioritize > Plan > Monitor]
Why “De-prescribing” Matters
As patients age, the benefit-to-risk ratio of certain preventive drugs shifts. What was beneficial at age 50 may become a burden at age 85.
| Factor | Risk of Over-Medication (Polypharmacy) |
| Adverse Drug Reactions | Older metabolism processes drugs slower, leading to higher toxicity risk. |
| Drug Interactions | Taking 5+ medications significantly increases the chance of harmful interactions. |
| Physical Hazards | Certain BP meds can cause dizziness, leading to falls and hip fractures. |
| Treatment Burden | The mental and financial stress of managing dozens of daily pills. |
A Note on “Low Evidence Certainty”
Despite the encouraging results, the researchers issued a caveat. The “evidence certainty”—the statistical confidence that the research perfectly reflects reality—was rated as low.
- The Need for Trials: Most existing data comes from observational studies rather than large-scale Randomized Controlled Trials (RCTs).
- Clinical Judgment: Experts emphasize that de-prescribing should never be done by the patient alone; it must be a supervised clinical decision tailored to the individual’s specific health status and goals.
Sources
- BMC Geriatrics: “Effect of de-prescribing preventive medications on mortality and health outcomes in frail older adults: A systematic review” (Published March 2026).
- Press Trust of India (PTI): “Stopping preventive drugs in elderly not linked to mortality, hospitalisation: Analysis” (March 27, 2026).
- Karolinska Institutet Press: “New research questions lifelong preventive medication for the frail elderly” (March 26, 2026).
- ICMR Bulletin: “Geriatric Health Update: De-prescribing Protocols” (March 2026).
Leave a Reply